li001

CLL17 and FLAIR Trials Highlight Shift Toward Personalized, Time-Limited Therapy in chronic lymphocytic leukemia

Research Advances /

Two major phase 3 trials, CLL17 and FLAIR, are reshaping treatment for chronic lymphocytic leukemia by comparing continuous therapy with time-limited, personalized approaches. The CLL17 trial compared three chemotherapy-free options: continuous Ibrutinib, time-limited Venetoclax plus Obinutuzumab, and time-limited Ibrutinib plus Venetoclax. All showed similar effectiveness, with about 95% progression-free survival at three years. However, patients […]

CLL17 and FLAIR Trials Highlight Shift Toward Personalized, Time-Limited Therapy in chronic lymphocytic leukemia Read More »

Enfortumab Vedotin Plus Pembrolizumab Sets New Standard in Urothelial Cancer, Researchers Explore Next-Gen ADCs

Treatment /

The combination of enfortumab vedotin and pembrolizumab has reshaped treatment for urothelial cancer, showing strong results across multiple stages of the disease. In metastatic patients, it nearly doubled median overall survival compared to chemotherapy (31.5 vs. 16.1 months). In perioperative settings for cisplatin-ineligible muscle-invasive bladder cancer, it reduced the risk of progression or death by

Enfortumab Vedotin Plus Pembrolizumab Sets New Standard in Urothelial Cancer, Researchers Explore Next-Gen ADCs Read More »

Cadonilimab Shows Durable Survival in Advanced Cervical Cancer, Effective Across PD-L1 Status

Immunotherapy /

Long-term results from the COMPASSION-03 trial show that cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, offers lasting survival benefits for patients with recurrent or metastatic cervical cancer who have failed prior chemotherapy. Patients who achieved complete responses had a 100% survival rate at 24 months, while partial responders showed a 63% survival rate, with a median

Cadonilimab Shows Durable Survival in Advanced Cervical Cancer, Effective Across PD-L1 Status Read More »

Belzutifan Expands Treatment Options for Renal Cell Carcinoma, Shows Promise in Multiple Settings

Treatment /

New results from the ASCO Genitourinary Cancers Symposium highlight advances in renal cell carcinoma (RCC) treatment, focusing on the use of belzutifan. In the adjuvant setting, the LITESPARK-022 trial showed that combining belzutifan with pembrolizumab improved disease-free survival compared with pembrolizumab alone. While high-grade side effects were more frequent, most patients tolerated treatment, suggesting this

Belzutifan Expands Treatment Options for Renal Cell Carcinoma, Shows Promise in Multiple Settings Read More »

Tislelizumab Plus Chemotherapy Improves Long-Term Survival in Nasopharyngeal Cancer

Immunotherapy /

Three-year follow-up results from the Phase 3 RATIONALE-309 trial show that adding tislelizumab to chemotherapy significantly improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma. Patients receiving the combination of tislelizumab with chemotherapy lived longer and had better disease control compared to chemotherapy alone. Median progression-free survival was 9.6 months versus 7.4 months, while

Tislelizumab Plus Chemotherapy Improves Long-Term Survival in Nasopharyngeal Cancer Read More »

CAN-2409 Tumor Vaccine Shows Promising Survival Gains in Advanced Lung Cancer

Immunotherapy /

Extended follow-up from a Phase 2a trial shows that CAN-2409, an experimental “in situ” tumor vaccine, may significantly improve survival in patients with advanced non–small cell lung cancer (NSCLC) who no longer respond to immune checkpoint inhibitors. At 24 months, 50% of patients were still alive, an increase from earlier results. Median overall survival reached

CAN-2409 Tumor Vaccine Shows Promising Survival Gains in Advanced Lung Cancer Read More »

FDA Approves MyChoice CDx to Expand Access to Niraparib in Ovarian Cancer

News, Precision Medicine /

The U.S. Food and Drug Administration has approved MyChoice® CDx as the first companion diagnostic test to identify patients with HRD-positive advanced ovarian cancer who can benefit from the PARP inhibitor niraparib. MyChoice CDx uses advanced genetic sequencing to analyze BRCA1/2 genes and signs of genomic instability, helping find about 34% more eligible patients compared

FDA Approves MyChoice CDx to Expand Access to Niraparib in Ovarian Cancer Read More »

New Hydrogel Model Mimics Tumor Stiffening in Pancreatic Ductal Adenocarcinoma to Improve Cancer Research

Research Advances /

Scientists have created a new hydrogel model that mimics how pancreatic tumors become stiffer over time, offering a more realistic way to study Pancreatic Ductal Adenocarcinoma (PDAC). The advance could help researchers better understand why this aggressive cancer resists treatment and spreads so easily. PDAC tumors are surrounded by a dense, stiff environment caused by

New Hydrogel Model Mimics Tumor Stiffening in Pancreatic Ductal Adenocarcinoma to Improve Cancer Research Read More »

Mayo Clinic Develops Milk-Based Nanoparticle Gene Therapy for Targeted Treatment of Cholangiocarcinoma

Targeted Therapy /

Researchers at Mayo Clinic have developed a new targeted gene therapy approach for cholangiocarcinoma, a rare and aggressive bile duct cancer. The study, published in JHEP Reports, introduces a precision method that delivers treatment directly to cancer cells while limiting damage to healthy tissue. The system uses small interfering RNA (siRNA) to switch off genes

Mayo Clinic Develops Milk-Based Nanoparticle Gene Therapy for Targeted Treatment of Cholangiocarcinoma Read More »

Scientists Identify MAP4K2 as Key Switch to Boost Cancer Immunity or Control Autoimmunity

Research Advances /

New research has identified MAP4K2 as a key regulator of regulatory T cells (Tregs), offering a new way to control the immune system in both cancer and autoimmune diseases. The study shows that MAP4K2 controls the production of FOXP3, a protein essential for turning regular T cells into suppressive Tregs. It does this by interacting

Scientists Identify MAP4K2 as Key Switch to Boost Cancer Immunity or Control Autoimmunity Read More »